Bridgebio Pharma SEC Filings

BridgeBio Pharma, Inc. reported an insider equity transaction by its President and CFO. On 12/12/2025, 13,826 shares of the company’s common stock were withheld at $75.15 per share to cover the executive’s tax obligations related to equity compensation.

The tax withholding was connected to the vesting of 25,000 shares of common stock underlying the executive’s restricted stock units. Following this transaction, the reporting officer directly beneficially owns 369,004 shares of BridgeBio Pharma common stock.

BridgeBio Pharma, Inc. reported an equity transaction by its Chief Accounting Officer, Maricel Apuli. On 12/12/2025, 2,003 shares of common stock were withheld to satisfy the officer's tax obligation arising from the vesting of 3,944 restricted stock units. The transaction price reported for the withheld shares was $75.15 per share. After this withholding, the officer beneficially owned 128,294 shares of BridgeBio Pharma common stock in direct ownership.

BridgeBio Pharma, Inc. (BBIO) Chief Executive Officer and director Kumar Haldea reported open-market sales of the company’s common stock on 11/20/2025 under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. He sold 6,401 shares at a weighted average price of $64.9706, 14,299 shares at a weighted average price of $65.904, and 5,456 shares at a weighted average price of $66.7129, with each price reflecting sales across specified ranges. Following these transactions, Haldea directly held 228,776 shares and also had indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust, where he serves as co-trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.

BridgeBio Pharma, Inc. (BBIO) director insider transactions were reported on a Form 4. A reporting person serving as a director disclosed open-market sales of BridgeBio common stock on 11/17/2025 and 11/18/2025 at weighted average prices ranging from about $64.58 to $67.20 per share, with specific weighted averages of $66.6263, $67.056, $65.2315, and $66.049 for the reported trades.

Following these transactions, the director beneficially owned 17,887 shares of common stock directly and 50,583 shares indirectly through joint tenancy with Nancy N. Lo. The price ranges for each trade are available, and the reporting person has undertaken to provide detailed breakdowns of the individual sale prices within each range upon request.

BridgeBio Pharma, Inc. (BBIO) director reports option exercise and share sales. On 11/17/2025, the reporting person exercised a stock option for 10,000 shares of common stock at $16.75 per share, increasing their holdings before subsequent sales. That same day, they sold 3,801 shares of common stock at a weighted average price of $66.2481 and 6,199 shares at a weighted average price of $66.8908, all under a Rule 10b5-1 trading plan adopted on June 27, 2025. After these transactions, the reporting person directly owned 11,589 shares of BridgeBio common stock and indirectly owned 4,000 shares through Thinking Bench Capital LLC. Following the option exercise, 41,501 stock options with a $16.75 exercise price remained beneficially owned.

BridgeBio Pharma (BBIO) Chief Executive Officer and director Kumar Haldea reported routine equity activity on a Form 4 dated 11/16/2025. Several blocks of restricted stock units (RSUs) were converted into common stock as they vested, and a portion of the resulting shares was withheld to cover taxes.

Following these transactions, Haldea directly owns 254,932 shares of BridgeBio common stock. He also reports indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust, where he is a co‑trustee and disclaims beneficial ownership beyond any pecuniary interest. The RSU awards vest quarterly over time as long as he continues serving the company, and the RSUs carry no expiration date.

BridgeBio Pharma, Inc. (BBIO) President and CFO reported stock transactions involving company common shares. On 11/16/2025, 21,317 shares were withheld to cover taxes upon vesting of 38,547 restricted stock units. On 11/17/2025, he sold 9,978 shares at a weighted average price of $66.1923 and 6,956 shares at a weighted average price of $66.8398, with sales executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. Following these transactions, he beneficially owns 382,830 BridgeBio common shares directly.

BridgeBio Pharma, Inc. (BBIO) reported an insider equity transaction by its Chief Accounting Officer on a Form 4. On 11/16/2025, the officer had 4,781 shares of common stock withheld, coded as transaction type "F," at a price of $66.39 per share. This withholding was used to cover tax obligations tied to the vesting of 9,410 shares of common stock underlying restricted stock units.

After this tax withholding, the reporting person beneficially owns 132,297 shares of BridgeBio Pharma common stock in direct ownership. The filing notes that the transaction relates to routine equity compensation vesting and associated tax settlement, rather than an open-market purchase or sale.

BridgeBio Pharma (BBIO) insider filed a Form 4 reporting open‑market sales totaling 80,000 shares of common stock on 11/06/2025 and 11/07/2025, executed under a Rule 10b5-1 trading plan adopted on March 31, 2025.

Sales were made through trusts where the reporting person is a co‑trustee at weighted average prices within disclosed ranges, with individual trades priced from $60.57 to $64.39 per share. Following these transactions, beneficial holdings reported include 4,598,447 shares (Revocable Trust), 795,686 shares (Family Irrevocable Trust), and 223,090 shares held directly.